SBS | Jotup

AG&P LNG Awarded 20-year Contract by PLN EPI, Indonesia for Co-development, Ownership and Operations of LNG Import Terminals in Sulawesi-Maluku Power Cluster

Retrieved on:

Tuesday, March 26, 2024

Energi, Carbon, SBS, Natural gas, MTPA, JV, AG, Partnership, Acquisition, LNG carrier, PLN, Consortium, Plant, Investment, FSRU, PT PLN

SINGAPORE, March 26, 2024 /PRNewswire/ -- Leading LNG terminals and downstream infrastructure company, AG&P LNG, majority-owned by Nebula Energy, announced today that its subsidiary PT AGP Indonesia Utama (AG&P Indonesia), along with consortium members Suasa Benua Sukses (SBS) and KPMOG, collectively referred to as the Consortium, has won a large-scale 20-year contract for LNG infrastructure from PLN EPI in Indonesia. The tender was awarded to AG&P LNG for the co-development, ownership and operations of LNG import terminal infrastructure and downstream logistics in seven locations within the Sulawesi-Maluku cluster in Indonesia. The customer and co-shareholder in this facility will be PT PLN Energi Primer (PLN EPI), a wholly owned subsidiary of PT PLN (Persero) Indonesia.

Key Points:

PT PLN Energi Primer (PLN EPI), a wholly owned subsidiary of PT PLN (Persero) Indonesia will be the customer and co-shareholder in the facility.
The tender was awarded to AG&P LNG for the co-development, ownership and operations of LNG import terminal infrastructure and downstream logistics in seven locations within the Sulawesi-Maluku cluster in Indonesia.
The customer and co-shareholder in this facility will be PT PLN Energi Primer (PLN EPI), a wholly owned subsidiary of PT PLN (Persero) Indonesia.
Among its LNG terminal project portfolio, AG&P LNG is the operator of the first LNG import and regasification terminal in the Philippines, the Philippines LNG (PHLNG) Import Terminal located in Batangas Bay.

AG&P LNG Awarded 20-year Contract by PLN EPI, Indonesia for Co-development, Ownership and Operations of LNG Import Terminals in Sulawesi-Maluku Power Cluster

Retrieved on:

Tuesday, March 26, 2024

Energi, Carbon, SBS, Natural gas, MTPA, JV, AG, Partnership, Acquisition, LNG carrier, PLN, Consortium, Plant, Investment, FSRU, PT PLN

SINGAPORE, March 26, 2024 /PRNewswire/ -- Leading LNG terminals and downstream infrastructure company, AG&P LNG, majority-owned by Nebula Energy, announced today that its subsidiary PT AGP Indonesia Utama (AG&P Indonesia), along with consortium members Suasa Benua Sukses (SBS) and KPMOG, collectively referred to as the Consortium, has won a large-scale 20-year contract for LNG infrastructure from PLN EPI in Indonesia. The tender was awarded to AG&P LNG for the co-development, ownership and operations of LNG import terminal infrastructure and downstream logistics in seven locations within the Sulawesi-Maluku cluster in Indonesia. The customer and co-shareholder in this facility will be PT PLN Energi Primer (PLN EPI), a wholly owned subsidiary of PT PLN (Persero) Indonesia.

Key Points:

PT PLN Energi Primer (PLN EPI), a wholly owned subsidiary of PT PLN (Persero) Indonesia will be the customer and co-shareholder in the facility.
The tender was awarded to AG&P LNG for the co-development, ownership and operations of LNG import terminal infrastructure and downstream logistics in seven locations within the Sulawesi-Maluku cluster in Indonesia.
The customer and co-shareholder in this facility will be PT PLN Energi Primer (PLN EPI), a wholly owned subsidiary of PT PLN (Persero) Indonesia.
Among its LNG terminal project portfolio, AG&P LNG is the operator of the first LNG import and regasification terminal in the Philippines, the Philippines LNG (PHLNG) Import Terminal located in Batangas Bay.

SBS TO RECEIVE MULTIMILLION DOLLAR SETTLEMENT FROM VOZ MEDIA

Retrieved on:

Monday, March 18, 2024

OTC Markets Group, SBS, Acquisition, VOZ

MIAMI, March 18, 2024 /PRNewswire/ -- Spanish Broadcasting System, Inc. ("SBS" or "the Company") (OTC Pink: SBSAA) announced today that it had reached a multimillion dollar out-of-court settlement with VOZ Media regarding VOZ's default of its $64 Million acquisition of the SBS Mega TV division.

Key Points:

MIAMI, March 18, 2024 /PRNewswire/ -- Spanish Broadcasting System, Inc. ("SBS" or "the Company") (OTC Pink: SBSAA) announced today that it had reached a multimillion dollar out-of-court settlement with VOZ Media regarding VOZ's default of its $64 Million acquisition of the SBS Mega TV division.
The amount of the settlement was not disclosed.
The settlement is in addition to a $3.8 Million deposit SBS had previously retained after VOZ failed to close on the TV transaction in 2023.
An SBS spokesperson stated that the Company was pleased with the out-of-court settlement and the outcome of the litigation.

Standard BioTools Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on:

Wednesday, February 28, 2024

Standard, Total, Doctor of Philosophy, Investment, News, Table, Supplement, Appendix, Egholm, Instrument, Event, GAAP, SomaLogic, Webcast, Standard BioTools, Research, SBS, Video game

Standard BioTools will host a conference call and webcast today at 1:30 p.m. PT, 4:30 p.m.

Key Points:

Standard BioTools will host a conference call and webcast today at 1:30 p.m. PT, 4:30 p.m.
ET, to discuss fourth quarter and full year 2023 financial results and operational progress as well as to provide additional color on its strategic actions.
The non-GAAP financial measures included in this press release are non-GAAP gross margin, non-GAAP operating expenses, and adjusted EBITDA.
Standard BioTools encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliations between these presentations, to more fully understand its business.

LiVDerm’s 22nd Annual South Beach Symposium Achieves Outstanding Success in Miami Beach

Retrieved on:

Thursday, February 22, 2024

Education, Pediatric Dermatology, Exhibition, Dermatology, Calendar, Catalog, Learning, Skin care, Faculty, Health, JD, Patient, Master, Knowledge, SBS, Student, Nursing

Hosted side by side, these two annual events brought together leading experts, practitioners, and industry professionals to exchange knowledge, share insights, and advance dermatologic care.

Key Points:

Hosted side by side, these two annual events brought together leading experts, practitioners, and industry professionals to exchange knowledge, share insights, and advance dermatologic care.
Attendees had the opportunity to engage with renowned faculty members and explore the latest advances in both medical and cosmetic dermatology.
The enhanced exhibition hall served as a hub of innovation and networking, further enriching the symposium experience for all present.
"We are thrilled with the success of both symposia and the impact they've had on advancing dermatologic education and patient care.

Ironwood Pharmaceuticals Announces Positive Topline Results from Global Phase III Trial of Once-Weekly Apraglutide in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)

Retrieved on:

Thursday, February 29, 2024

Pharmaceutical, Health, Clinical Trials, FACS, SBS, FRCS, Principal, PS, Short bowel syndrome, Safety, Pelvic floor dysfunction, Patient, Transplant, Medication, Ironwood Pharmaceuticals, MBBS, NDA, Pharmaceutical industry

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced positive topline results from its pivotal Phase III STARS trial, which evaluated the efficacy and safety of once-weekly subcutaneous apraglutide in reducing parenteral support (PS) dependency in adult patients with short bowel syndrome with intestinal failure (SBS-IF).

Key Points:

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced positive topline results from its pivotal Phase III STARS trial, which evaluated the efficacy and safety of once-weekly subcutaneous apraglutide in reducing parenteral support (PS) dependency in adult patients with short bowel syndrome with intestinal failure (SBS-IF).
Based on these results, Ironwood plans to submit a new drug application (NDA) and other regulatory filings for apraglutide for use in adult patients with SBS who are dependent on PS.
The global, multicenter, double-blind, randomized, placebo-controlled trial evaluated the efficacy and safety of weekly subcutaneous injections of apraglutide in adult patients with SBS-IF.
Topline safety results were generally consistent with the safety profile demonstrated in apraglutide studies to date.

Ironwood Pharmaceuticals to Present Four Abstracts at the ASPEN 2024 Nutrition Science & Practice Conference

Retrieved on:

Friday, February 23, 2024

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, announced today that the company will present findings from four studies evaluating apraglutide in adults with short bowel syndrome with intestinal failure (SBS-IF), a condition in which they are dependent on parenteral support, during the American Society for Parenteral and Enteral Nutrition (ASPEN) 2024 Nutrition Science & Practice Conference.

Key Points:

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, announced today that the company will present findings from four studies evaluating apraglutide in adults with short bowel syndrome with intestinal failure (SBS-IF), a condition in which they are dependent on parenteral support, during the American Society for Parenteral and Enteral Nutrition (ASPEN) 2024 Nutrition Science & Practice Conference.
ASPEN is being held from March 2-5, 2024, in Tampa, Florida.
SBS is a serious and chronic condition where there is diminished absorptive capacity for fluids and/or nutrients, typically resulting from extensive intestinal resection.
“These findings continue to deepen our understanding of GLP-2 and the potential of apraglutide to help adult patients with SBS who are dependent on PS, including those with colon-in-continuity.

Axway Announces Entering Into Exclusive Discussions to Acquire Most of Sopra Banking Software Activities

Retrieved on:

Wednesday, February 21, 2024

Axway (Paris:AXW) today announces entering into exclusive discussions regarding the potential acquisition of most of Sopra Banking Software (“SBS”) activities, which are currently part of Sopra Steria Group.

Key Points:

Axway (Paris:AXW) today announces entering into exclusive discussions regarding the potential acquisition of most of Sopra Banking Software (“SBS”) activities, which are currently part of Sopra Steria Group.
Axway would acquire the SBS activities concerned by the operation for an enterprise value of €330m.
Sopra Steria granted exclusive rights to Axway and Sopra GMT to negotiate the envisaged transactions.
Pierre Pasquier, Chairman of Axway, Sopra Steria and Sopra GMT, declared:
"Axway's proposed acquisition of most of SBS's activities represents an undeniable strategic opportunity for both companies.

Sharp Business Systems Named to CRN's MSP 500 List

Retrieved on:

Thursday, March 7, 2024

Managed services, Senior, CRN, Sharp, MSP, The Channel Company, Growth, Service provider, Sharp Corporation, Elite, SBS, Management

MONTVALE, N.J., March 7, 2024 /PRNewswire/ -- Sharp Imaging and Information Company of America (SIICA), a division of Sharp Electronics Corporation (SEC), today announced that CRN ® , a brand of The Channel Company , has named its direct sales division, Sharp Business Systems (SBS), to its Managed Service Provider (MSP) 500 list in the Elite 150 category for 2024.

Key Points:

MONTVALE, N.J., March 7, 2024 /PRNewswire/ -- Sharp Imaging and Information Company of America (SIICA), a division of Sharp Electronics Corporation (SEC), today announced that CRN ® , a brand of The Channel Company , has named its direct sales division, Sharp Business Systems (SBS), to its Managed Service Provider (MSP) 500 list in the Elite 150 category for 2024.
The MSP 500 list compiled by CRN serves as a comprehensive guide to identifying and recognizing the top Managed Service Providers (MSPs) in North America.
Sharp was selected to the MSP 500 list because of the robust portfolio of managed IT services that it offers to a variety of vertical industries, ensuring efficiency and productivity.
The annual MSP 500 list is divided into three sections: the MSP Pioneer 250, MSP Elite 150, and the Managed Security 100.

NanoMosaic launches AAV gene therapy bioprocessing and manufacturing QC assays for simultaneous capsid & transgene interrogation with high standardization

Retrieved on:

Wednesday, March 6, 2024

Doctor of Philosophy, University of Massachusetts, Capsid, Microbiology, Transgene, Genetic, GEN, Dicarboxylic acid, Data analysis, Protein, Patient safety, Heart, Mary Ann Liebert, QC, AAV, Research, SBS, Workflow, Vaccine

The assays are seamlessly deployable across upstream and downstream stages of the gene therapy workflow, while harmonizing the data from bioprocessing to batch release QC.

Key Points:

The assays are seamlessly deployable across upstream and downstream stages of the gene therapy workflow, while harmonizing the data from bioprocessing to batch release QC.
"The objectives pursued by NanoMosaic are positive steps forward for a space desperate for a fit-for-purpose tool that can be standardized throughout the entire gene therapy development and manufacturing processes.
"NanoMosaic is excited to offer a unique solution to a challenging and fast-growing gene therapy market," said Qimin Quan, PhD, co-founder and Chief Scientific Officer.
NanoMosaic will feature the platform and unique gene therapy applications in a live broadcast scientific webinar alongside industry leaders on March 26, 2024, hosted by Genetic Engineering News (GEN).